Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.34 |
| ▸ | XBP1 | P17861 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473069 | 0.88 | TRPV4 (0.46) | TRPV4KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL16604331 | 0.87 | TRPV4 (0.47) | TRPV4PDE9ADHODHLMNAALDH1A1 | |
| SCHEMBL16681130 | 0.84 | TRPV4 (0.43) | TRPV4KDM4EPDE9ADHODHLMNA | |
| SCHEMBL21563310 | 0.84 | TRPV4 (0.43) | TRPV4KDM4EPDE9ADHODHLMNA | |
| SCHEMBL14601371 | 0.84 | SELL (0.46) | TRPV4KDM4EPDE9ADHODHALDH1A1 | |
| SCHEMBL16545828 | 0.84 | TRPV4 (0.43) | TRPV4KDM4EPDE9ADHODHLMNA | |
| SCHEMBL31531374 | 0.84 | TRPV4 (0.43) | TRPV4KDM4EPDE9ADHODHLMNA | |
| SCHEMBL12889551 | 0.82 | TRPV4 (0.42) | TRPV4KDM4EPDE9ALMNAALDH1A1 | |
| SCHEMBL14075237 | 0.81 | TRPV4 (0.45) | TRPV4KDM4EPDE9ALMNAALDH1A1 | |
| SCHEMBL21393400 | 0.80 | TRPV4 (0.39) | TRPV4KDM4EPDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025007873-A1 | KAT6 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2025-01-09 | — | — | WO | disclosed |
| EP-3863638-B1 | PHOSPHODIESTERASE INHIBITORS | UNIV NEBRASKA (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022117551-A1 | LIQUID CRYSTALLINE MEDIUM AND ELECTRO-OPTICAL DEVICE | MERCK PATENT GMBH (DE) | 2022-06-09 | — | — | WO | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20080167482-A1 | mesogenic group is linked to the C-atom No. 5 of the 1,3-dioxane-5-yl group; media showing a blue phase and their use in electro-optical light modulation elements | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1116770-B1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY USING THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-7335404-B2 | Liquid crystal composition for use in bistable liquid crystal devices | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-26 | — | — | US | disclosed |
| US-7314943-B2 | Pyran derivatives containing an exocyclic double bond | MERCK PATENT GMBH (DE) | 2008-01-01 | — | — | US | disclosed |
| US-7314943-B2 | Pyran derivatives containing an exocyclic double bond | MERCK PATENT GMBH (DE) | 2008-01-01 | — | — | US | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-7198827-B1 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7198827-B1 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| US-7166337-B2 | Liquid-crystal composition, methods of adjusting the resistance, and substituted phenols | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | TRPV4 929/4885KDM4E 1271/4885PDE9A 2796/4885 |
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CDR2 | TRPV4 4814/4885KDM4E 1281/4885PDE9A 3163/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | TRPV4 88/4885KDM4E 4736/4885PDE9A 451/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | TRPV4 128/4885KDM4E 1956/4885PDE9A 2174/4885 |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, KDM1A, HDAC1 | TRPV4 3094/4885KDM4E 23/4885PDE9A 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.